JNJ-55920839在健康志愿者和系统性红斑狼疮患者中的首次人体研究:随机安慰剂对照1期试验
共纳入48名健康志愿者和28例SLE患者,随机(3:1)接受药物或安慰剂。最常见治疗中出现的不良事件为感染和侵染,JNJ-55920839组感染比例高于安慰剂组;两例SLE患者报告局部播散性带状疱疹。结论认为JNJ-55920839耐受性良好且安全,需进一步研究确定最佳剂量。
要点
- JNJ-55920839在健康志愿者和SLE患者中总体耐受性良好且安全。
- 感染和侵染是最常见治疗中出现的不良事件,JNJ-55920839组发生率高于安慰剂组。
- 两例SLE患者报告局部播散性带状疱疹。
核心结论
- JNJ-55920839耐受性良好且安全,需进一步研究确定患者最佳剂量并探索安全性。
研究设计与样本
- 纳入18-55岁健康志愿者(A部分,体重50-90 kg,BMI 18-30 kg/m2)及轻中度SLE患者(B部分,体重40-100 kg),随机(3:1)接受JNJ-55920839或安慰剂。
- 主要结局为通过临床和实验室检查评估研究方案的安全性与耐受性,并与安慰剂比较。
主要发现
- 2015年12月11日至2018年9月20日,共纳入48名健康志愿者(单中心)和28例轻中度SLE患者(7国19中心)。
- A部分12名健康志愿者和B部分8例SLE患者接受安慰剂。
- A部分和B部分最常见治疗中出现的不良事件均为感染和侵染,JNJ-55920839组感染比例高于安慰剂组:A部分10/36(28%) vs 2/12(17%),B部分9/18(50%) vs 1/8(13%)。
- 两例SLE患者报告局部播散性带状疱疹;除JNJ-55920839治疗者观察到的感染外,未发现其他有临床意义的安全性或不耐受问题。
临床怎么用
- 该1期研究提示JNJ-55920839在健康志愿者和轻中度SLE患者中总体安全耐受,但JNJ-55920839组感染发生率高于安慰剂组,临床使用时需关注感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activation of the type I interferon (IFN) pathway is associated with systemic lupus erythematosus (SLE). We assessed the safety and tolerability of JNJ-55920839, a human monoclonal antibody that selectively neutralises most human IFNα subtypes and IFNω, in healthy participants and those with SLE. METHODS: This was a two-part, first-in-human, phase 1, randomised, double-blind, placebo-controlled, multicentre study of single-ascending intravenous doses of 0·3-15 mg/kg or a single subcutaneous dose of 1 mg/kg JNJ-55920839 administered to healthy participants (part A) and multiple intravenous doses of 10 mg/kg JNJ-55920839 administered to participants with SLE (part B). Healthy men and women (women had to be postmenopausal or surgically sterile) aged 18-55 years; bodyweight of 50-90 kg; and body-mass index (BMI) of 18-30 kg/m2 were eligible for inclusion in part A. Men and women with SLE were recruited to part B, fertile female participants were required to have a negative pregnancy test result before and during the study and be using two highly effective methods of birth control. The inclusion criteria for participants with SLE in part B matched part A, except for bodyweight (40-100 kg). In both parts, participants were randomly assigned (3:1) to receive JNJ-55920839 or placebo; a computer-generated randomisation schedule was used in part A, and randomisation was stratified by racial and ethnic subpopulation and elevated levels of serological disease activity in part B. The primary outcome was evaluation of safety and tolerability of the study regimen assessed using clinical and laboratory tests compared with placebo. This study is registered with ClinicalTrials.gov, NCT02609789. FINDINGS: Between Dec 11, 2015, and Sept 20, 2018, 48 healthy participants from a single site and 28 participants with mild-to-moderate SLE from 19 participating centres in seven countries were enrolled in the study. 12 healthy volunteers in part A and eight participants with SLE in part B received placebo. The most common treatment-emergent adverse events in both part A and B were in the system organ class of infections and infestations with a higher percentage of participants administered JNJ-55920839 with infections (ten [28%] of 36 in part A and nine [50%] of 18 in part B) than those exposed to placebo (two [17%] of 12 in part A and one [13%] of eight in part B). Particpants in part B were permitted to continue on defined ongoing standard of care medications. In two participants with SLE, locally disseminated herpes zoster of the skin was reported. No other clinically significant safety or tolerability issues were identified beyond the infections observed in participants treated with JNJ-55920839. INTERPRETATION: JNJ-55920839 was well tolerated and safe. Additional studies are warranted to determine optimal dosing of patients and further explore safety. FUNDING: Janssen.
引用
- Jordan J, Benson J, Chatham WW, et al. First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial. Lancet Rheumatol. 2020. PMID: 38273624. doi:10.1016/S2665-9913(20)30223-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。